Company news

Intelligent Bio Solutions Inc. news in 2024

Intelligent Bio Solutions Inc.'s news releases, calls and decks from 2024, newest first.

View company

Intelligent Bio Solutions Announces 510(k) Submission to US FDA for Fingerprint Sweat-Based Drug Screening Technology

December 17, 2024

Intelligent Bio Solutions Achieves 94.1% Accuracy in Method Comparison Study, Following Positive PK Study Results

November 25, 2024

Intelligent Bio Solutions Announces Positive Results of PK Study, a Key Milestone on Path to FDA 510(k) Submission

November 12, 2024

Intelligent Bio Solutions Reports Fiscal 2025 First Quarter Financial Results and Operational Highlights

November 6, 2024

Intelligent Bio Solutions Partners with B2i Digital to Amplify Investor Outreach

October 30, 2024

Intelligent Bio Solutions Announces Preliminary Unaudited Fiscal 2025 First Quarter Revenue Results

October 28, 2024

Intelligent Bio Solutions Announces Adoption of its Non-Invasive Drug Screening Solution by Global Engineering Leader, Pyrotek

October 13, 2024

Intelligent Bio Solutions Partners with Spirit Group as Australian Distributor, Expanding Community Impact with Intelligent Fingerprinting Drug Testing Solution

October 8, 2024

Intelligent Bio Solutions Concludes In-Clinic Testing for Clinical Study Plan, Advancing Toward FDA 510(k) Submission

September 26, 2024

Intelligent Bio Solutions Inc. Reports Fiscal 2024 Fourth Quarter and Full Year Financial Results and Operational Highlights

September 18, 2024

Intelligent Bio Solutions Inc. Announces Preliminary Full Fiscal Year 2024 Revenue Growth of 148% Year-Over-Year

September 8, 2024

Intelligent Bio Solutions Inc. Announces Progress Toward Completion of Clinical Study Plan Required for FDA 510(k) Submission

September 4, 2024

Intelligent Bio Solutions Inc. Achieves Major Milestone with Over 1,000 Installed Intelligent Fingerprinting Drug Screening Readers as of June 30, 2024

August 20, 2024

Intelligent Bio Solutions Partners with CenExel to Conduct Clinical Study as Part of FDA 510(k) Pathway

July 31, 2024

Intelligent Bio Solutions Inc. Announces QabasTech as Exclusive Distributor in Saudi Arabia

July 23, 2024

Intelligent Bio Solutions Inc. Advances on FDA 510(k) Pathway with Biocompatibility Study Success

July 17, 2024

Intelligent Bio Solutions Strengthens UK Market Position with Addition of Key Manufacturing Accounts

July 8, 2024

Intelligent Bio Solutions Completes In-Clinic Portion of Pharmacokinetic (PK) Study Part of 510(k) Pathway for Approval & Commences Review of Results

June 27, 2024

Intelligent Bio Solutions Broadens UK Customer Base by Securing Two Key Accounts with Over 70 Locations and Over 15,000 Employees in the Warehouse and Logistics Sector

June 19, 2024

Intelligent Bio Solutions Begins Subject Dosing and Sampling for FDA 510(k) Pharmacokinetic (PK) Study for its Intelligent Fingerprinting Drug Screening Technology

June 17, 2024

Intelligent Bio Solutions Implements Strategic Reorganization Plan to Support Global Growth Initiatives

June 12, 2024

Intelligent Bio Solutions Inc. Reports Fiscal 2024 Third Quarter and Nine-Month Financial Results and Operational Highlights

May 7, 2024

Intelligent Bio Solutions Inc. Announces Preliminary Unaudited Fiscal Third Quarter and Nine-Month Revenue Results

April 17, 2024

Intelligent Bio Solutions Announces $10.1 Million Private Placement Priced At-the-Market Under Nasdaq Rules

March 10, 2024

Intelligent Bio Solutions Partners with Cliantha Research to Conduct Clinical Study as Part of FDA 510(k) Pathway

February 27, 2024

Intelligent Bio Solutions Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement and Confirms Compliance with Minimum Stockholders’ Equity Requirement

February 15, 2024

Intelligent Bio Solutions Inc. Reports Fiscal Second Quarter and Six-Month Financial Results and Operational Highlights

February 8, 2024

Intelligent Bio Solutions Inc. Announces Exercise of Previously Issued Warrants for $1.77 Million in Gross Proceeds

February 4, 2024

Intelligent Bio Solutions Inc. Announces Preliminary Unaudited Fiscal Second Quarter and Six-Month Revenue Results

February 1, 2024

Decks in 2024